Dr. Eric Morgen on The BioAge Platform: From Biomarkers to Drug Trials and Back at EARD 2022

Dr. Eric Morgen of BioAge presents "The BioAge Platform: From Biomarkers to Drug Trials and Back" at the Ending Age-Related Diseases 2022 Conference.
SUMMARY
▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀
In Dr. Eric Morgen's speech at BioAge, he discusses the BioAge platform, rooted in human omics data, which is used to generate biomarkers and shed light on mechanisms related to aging. BioAge is a clinical-stage biotechnology company focused on developing therapeutics that target the root causes of aging. Dr. Morgen emphasizes the importance of extending human healthspan and lifespan by addressing aging mechanisms and shares inspiring examples from nature.
The speech highlights the data-driven approach employed by BioAge, which leverages artificial intelligence and multiomics data to decode biomarkers and aging biology. The platform collects data from healthy aging cohorts and identifies key molecular differences associated with varying aging trajectories. It delves into the natural human experiment that occurs as people age.
Dr. Morgen provides insights into the power of AI and multiomics to discover aging biomarkers, functional relationships, and underlying mechanisms. The platform identifies potential drug targets, such as apelin, and the talk emphasizes the importance of translating findings from animal models to human therapeutics.
The speech concludes by discussing how the platform's biomarkers can inform clinical trials and enhance patient selection and monitoring. Ultimately, BioAge aims to help patients "die young as late as possible."
___________________________________________
Eric Morgen, MD, MPH, FRCPC, is Co-founder and COO at BioAge Labs, a clinical-stage biopharmaceutical company advancing a broad pipeline of therapeutics to treat and prevent age-related diseases and extend human healthspan and lifespan. BioAge’s computational platform is rooted in longitudinal ‘omics and clinical data spanning more than 40 years and provides a powerful approach to select drug targets that can improve the way we age. Eric’s oversees the company’s clinical, computational, and cohort-based activities.
EARD 2022
▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀
www.lifespan.io/ending-age-re...
FOLLOW US
▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀
www.lifespan.io
/ lifespanio
/ lifespan.io
HOW CAN YOU SUPPORT US?
▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀
Lifespan.io, a 501(c)(3) nonprofit organization.
► Support us with monthly donations by becoming a Lifespan Hero: www.lifespan.io/hero
► Subscribe: / lifespanio
► Learn more, and help us: www.lifespan.io
#longevity #biotechnology #aging #biology #healthscience #biomarkers #startups #crypto #cryptocurrency #lifeextension #lifespan